Etranacogene dezaparvovec

Therapeutic indications

Etranacogene dezaparvovec is indicated for:

Severe and moderately severe Haemophilia B without Factor IX inhibitors

Population group: only adults (18 years old or older)

Etranacogene dezaparvovec is indicated for the treatment of severe and moderately severe Haemophilia B (congenital Factor IX deficiency) in adult patients without a history of Factor IX inhibitors.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Etranacogene dezaparvovec is contraindicated in the following cases:

Pregnancy

Pregnancy

Lactation

Lactation

Active infections

Infectious disease

Advanced liver fibrosis, liver cirrhosis

at least one of
Hepatic fibrosis
Cirrhosis of liver
Liver disorder due to infection

Blood, organ, tissue and cell donation

at least one of
Blood unit collection
Organ retrieval operation
Transplantation

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2023: HEMGENIX Concentrate for solution for infusion
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈